- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab 2018;20:5–21.
- Bastin M, Andreelli F. Dual GIP-GLP1-receptor agonists in the treatment of type 2 diabetes: a short review on emerging data and therapeutic potential. Diabetes Metab Syndr Obes 2019;12:1973–85.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 2018;18:3–14.
Tirzepatide in T2D
Key messages
- Combined GLP-1 and GIP receptor activation has synergistic and complementary actions.
- All tirzepatide doses were superior to placebo, long-acting GLP-1RA, and basal insulin in reducing HbA1c and body weight.
- Tirzepatide did not increase the odds of hypoglycaemia.
- Incidence of gastrointestinal side effects was similar to GLP-1RA, but increased versus placebo.
